• Publications
  • Influence
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
BACKGROUND Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2bExpand
  • 3,452
  • 89
Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States
Context Acute liver failure is a catastrophic condition affecting about 2000 persons in the United States each year. Contribution Among 308 consecutive patients with liver failure admitted to 1 of 17Expand
  • 1,789
  • 86
Acetaminophen‐induced acute liver failure: Results of a United States multicenter, prospective study
Severe acetaminophen hepatotoxicity frequently leads to acute liver failure (ALF). We determined the incidence, risk factors, and outcomes of acetaminophen‐induced ALF at 22 tertiary care centers inExpand
  • 1,502
  • 68
  • PDF
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
BACKGROUND Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, theseExpand
  • 1,206
  • 61
  • PDF
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
BACKGROUND & AIMS We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylatedExpand
  • 729
  • 34
  • PDF
AASLD position paper: The management of acute liver failure
These recommendations provide a data-supported approach. They are based on the following: 1) Formal review and analysis of recently-published world literature on the topic [Medline search]; 2)Expand
  • 695
  • 31
  • PDF
ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction and it can lead to jaundice, liver failure, or even death. Antimicrobials and herbal and dietary supplements are amongExpand
  • 395
  • 31
  • PDF
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.
  • Y. Loo, D. Owen, +15 authors M. Gale
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences…
  • 11 April 2006
Viral signaling through retinoic acid-inducible gene-I (RIG-I) and its adaptor protein, IFN promoter-stimulator 1 (IPS-1), activates IFN regulatory factor-3 (IRF-3) and the host IFN-alpha/betaExpand
  • 398
  • 31
  • PDF
Drug-induced hepatotoxicity.
  • W. Lee
  • Medicine
  • The New England journal of medicine
  • 26 October 1995
  • 853
  • 30
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
BACKGROUND & AIMS The most effective therapy currently available for treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin. This study evaluated theExpand
  • 486
  • 24